| 摘要 |
The invention relates to the use of a binding partner which binds to both SC R1 and SCR2 of CD55 in the treatment of tumours and leukaemia. The binding partner may be an antibody which binds to SCR1 and SCR2 of CD55 and neutralises CD55 thereby making cancer cells susceptible to complement mediated attack. |
